Go to main navigation Go to main content Go to footer

A phase II, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous injections of e10030 (anti-pdgf pegylated aptamer) given in combination with lucentis® in subjects with neovascular age-related macular degeneration

The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

untitled  untitled  untitled  untitled  untitled  untitled untitled
Subjects randomized in a 1:1:1 ratio to the following dose groups:
• E10030 0.3 mg/eye + Lucentis® 0. 5 mg/eye
• E10030 1.5 mg/eye + Lucentis® 0. 5 mg/eye
• E10030 sham + Lucentis® 0. 5 mg/eye
Subjects treated with active E10030 or sham E10030 in combination with Lucentis® at Day 0, Week 4, Week 8, Week 12, Week 16 and Week 20. All subjects had a final follow-up visit at Week 24.
Patients receiving the combination of Fovista (1.5 mg) and Lucentis® gained a mean of 10.6 letters of vision on the ETDRS standardized chart at 24 weeks, compared to 6.5 letters for patients receiving Lucentis® monotherapy (p=0.019), representing a 62% additional benefit. No significant safety issues were observed for either treatment group in the trial.

Research is the only solution for the future to fight against blindness

It is only with your help that we can fight against blindness

Collaborate